Glenmark Pharmaceuticals Inc., USA (Glenmark) announce it has launched their Fingolimod Capsules, 0.5 mg, the generic version of Gilenya1 Capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation.
According to IQVIA™ sales data for the 12-month period ending September 2022, the Gilenya Capsules, 0.5 mg market achieved annual sales of approximately $1.8 billion.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
